LYMPHOMA, FOLLICULAR
Clinical trials for LYMPHOMA, FOLLICULAR explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, FOLLICULAR trials appear
Sign up with your email to follow new studies for LYMPHOMA, FOLLICULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise in lymphoma study
Disease control OngoingThis study tests a combination of two drugs, mosunetuzumab and polatuzumab vedotin, in people with untreated follicular lymphoma. The drugs work together to help the immune system find and kill cancer cells. The goal is to see how many patients have their tumors completely disapp…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 10:30 UTC
-
New combo therapy aims to keep follicular lymphoma in check longer
Disease control OngoingThis study looks at whether adding lenalidomide to the standard drug rituximab (called R2) can help keep follicular lymphoma from coming back longer than rituximab alone. It involves 128 adults whose lymphoma returned after previous treatment and who cannot have a stem cell trans…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated May 26, 2026 10:29 UTC
-
New hope for lymphoma patients: drug combo aims for complete remission
Disease control OngoingThis study tests a new drug, golcadomide, combined with rituximab in 90 adults with newly diagnosed advanced follicular lymphoma who have not had prior treatment. The goal is to see if the combination can achieve complete metabolic response (disappearance of cancer signs on scans…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 10:26 UTC
-
Researchers monitor safety of lymphoma drug in Real-World use
Knowledge-focused OngoingThis study looks at the safety of the drug tazemetostat in 145 people in Japan who have a type of lymphoma (follicular lymphoma) that has come back or stopped responding to treatment and who have a specific gene change (EZH2 mutation). The study does not give any new treatment—it…
Matched conditions: LYMPHOMA, FOLLICULAR
Sponsor: Eisai Co., Ltd. • Aim: Knowledge-focused
Last updated May 26, 2026 10:34 UTC
-
CAR t cell recipients monitored for 15 years in safety study
Knowledge-focused OngoingThis study tracks about 50 people who previously received an experimental CAR T cell therapy for several types of lymphoma. The goal is to watch for long-term side effects and check how well patients do over 15 years. No new treatment is given, but patients can receive other canc…
Matched conditions: LYMPHOMA, FOLLICULAR
Sponsor: Adicet Therapeutics • Aim: Knowledge-focused
Last updated May 26, 2026 10:29 UTC